Cologuard stool DNA testing (FIT-DNA test) offers a non-invasive colorectal cancer screening option. Learn about Cologuard test codes for accurate clinical documentation and medical billing. This stool DNA test aids in the early detection of colon cancer and precancerous polyps. Understand the importance of Cologuard for healthcare professionals and patients seeking reliable colorectal cancer screening methods. Find information on Cologuard test procedures, result interpretation, and medical coding guidelines.
Also known as
Encounter for screening for colorectal cancer
Screening exam for colorectal cancer using stool DNA test.
Other fecal incontinence
May be relevant if stool sample collection is problematic.
Encounter for other specified special examinations
General code for encounters involving special diagnostic tests.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Cologuard being used for screening?
Yes
Is there a positive finding?
No
Is it diagnostic evaluation?
When to use each related code
| Description |
|---|
| Stool DNA test for colorectal cancer screening. |
| Fecal immunochemical test for occult blood. |
| Visual exam of colon and rectum. |
Cologuard, lacking a specific CPT code, may lead to incorrect unlisted code assignment, impacting reimbursement and data accuracy. Medical coding and CDI specialists should be aware.
Coverage for Cologuard requires specific criteria. Improper documentation of medical necessity can trigger payer denials. CDI and healthcare compliance audits are crucial.
Confusing Cologuard with FIT or other stool tests can result in incorrect ICD-10 coding, skewing data analysis and impacting quality reporting. Diligent medical coding is essential.
Q: How does Cologuard Stool DNA Testing compare to colonoscopy for colorectal cancer screening in average-risk patients, and when should each be considered?
A: Cologuard, a stool DNA test also known as a FIT-DNA test, offers a non-invasive alternative to colonoscopy for colorectal cancer screening in average-risk adults aged 45 and older. While colonoscopy remains the gold standard for visualization and removal of polyps, Cologuard analyzes stool for both altered DNA and blood, offering a more convenient approach for patients hesitant about invasive procedures. Colonoscopy detects more advanced precancerous lesions and cancers, allowing for immediate intervention during the procedure itself. However, it requires bowel preparation and carries risks of complications like perforation. Cologuard offers higher sensitivity for detecting cancer than fecal immunochemical test (FIT) alone, but lower sensitivity than colonoscopy. Positive Cologuard results necessitate a diagnostic colonoscopy. Clinicians should discuss both options with patients, considering their individual preferences, risk factors, and potential barriers to adherence. Consider implementing shared decision-making tools to help patients choose the best screening strategy for their needs. Explore how incorporating stool DNA testing into your practice can improve colorectal cancer screening rates.
Q: What are the specific indications and contraindications for ordering a Cologuard Stool DNA Test (FIT-DNA Test) in my clinical practice?
A: Cologuard is indicated for average-risk colorectal cancer screening in asymptomatic adults aged 45 and older. It's designed for individuals with no personal or family history of colorectal cancer, inflammatory bowel disease (IBD), or hereditary syndromes like Lynch syndrome. Cologuard is not a diagnostic test and should not be used in patients with symptoms suggestive of colorectal cancer, such as rectal bleeding or changes in bowel habits. Contraindications for Cologuard include a history of colorectal cancer, adenomatous polyps, IBD, or inherited colorectal cancer syndromes. These patients require more intensive surveillance and should undergo colonoscopy. Moreover, Cologuard is not recommended for individuals with a recent history of gastrointestinal bleeding, as this can lead to false-positive results. Learn more about appropriate patient selection for Cologuard to optimize the accuracy and effectiveness of your colorectal cancer screening program.
Patient presented for colorectal cancer screening. Discussion regarding screening options, including colonoscopy, fecal immunochemical test (FIT), and Cologuard stool DNA testing, was conducted. Patient declined colonoscopy due to [documented reason, e.g., scheduling conflicts, aversion to invasive procedures]. Risks and benefits of Cologuard, including its sensitivity and specificity for colorectal cancer and advanced adenomas, were explained. Patient elected to proceed with Cologuard, a non-invasive colorectal cancer screening test. Order placed for Cologuard stool DNA test (FIT-DNA test) collection kit. Patient education provided on proper specimen collection and handling. Importance of returning the kit promptly for processing was emphasized. Patient instructed to contact the office with any questions regarding the test procedure. Results will be reviewed upon receipt and appropriate follow-up, which may include colonoscopy if the Cologuard result is positive, will be scheduled. Medical necessity for colorectal cancer screening documented based on patient age, family history [if applicable], and current guidelines, including those from the US Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS). ICD-10 code Z12.11 (encounter for screening for malignant neoplasm of colon) assigned. CPT code 81528 (Colorectal cancer screening; stool DNA test) will be billed upon test completion and result interpretation.